Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • CLL • Hematology • Journal Club ft. NEJM publications
Is obinutuzumab obligatory with AV combination for patients with unmutated IGHV?
For which patients are you specifically adding obinutuzumab (or not)?
Answer from: Medical Oncologist at Academic Institution
Obinutuzumab certainly improves PFS and TTNT but it's important to recall that the OS (in the non-COVID-19 adjusted data) was inferior with AVO in the full cohort. I will certainly discuss adding obinutuzumab for patients with unmutated IgHV with all patients, but will recommend it only for patients...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
The toxicity data from AMPLIFY would suggest that AVO might not be the right combination for all patients with IGHV unmutated CLL. Although deaths in the study were primarily from COVID, it is not clear that this would not extrapolate to a higher risk from other viral infections overall. I would gen...
Answer from: Medical Oncologist at Academic Institution
Not necessarily, but they should be aware that the PFS may be relatively short, but they could likely repeat the treatment after that. I think 5-year data on PFS will be very helpful. At the moment, I am more inclined to use Ven obin or Acala ven obin.